<PAGE>

                                           *** TEXT OMITTED AND FILED SEPARATELY
                                                CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R.SECTIONS 200.80(b)(4),
                                                            200.83 AND 240.24b-2

                                                                   EXHIBIT 10.9

                              PHARSIGHT CORPORATION

                   INFORMATION PRODUCT DISTRIBUTION AGREEMENT

This Information Product Distribution Agreement (this "Agreement") is made and
entered into as of June 25, 1999 (the "Effective Date") by and between Pharsight
Corporation, a California corporation, (hereinafter "Pharsight") and Protocare
Sciences, Inc., a Delaware corporation (hereinafter "Protocare").

                                    RECITALS

Pharsight is engaged in the sale of software and services relating to clinical
trial design and modeling to pharmaceutical and biotechnology companies and
desires to have the right to reproduce, use, and distribute as part of its
Patient Information Resource (PIR) product a selection of patient therapeutic
data collected by Protocare in the diabetes area.

Protocare is the owner of or has appropriate licenses to all US and foreign
copyrights and all other intellectual property rights pertaining to the database
that is the subject of this Agreement and is willing to grant to Pharsight a
non-exclusive right and license to reproduce, use, and distribute that database
on the terms and conditions set forth herein.

NOW, THEREFORE, IN CONSIDERATION OF THESE PREMISES, AS WELL AS THE OBLIGATIONS
HEREIN MADE AND UNDERTAKEN, THE PARTIES HERETO DO HEREBY AGREE AS FOLLOW, WITH
THE CAPITALIZED TERMS HAVING THE MEANING SET FORTH IN EXHIBIT AS:

1. GRANT OF LICENSE.

1.1 LICENSE GRANT. Subject to the payment of royalties as set forth in Section
5, Protocare hereby grants Pharsight a non-exclusive world-wide right and
license (a) to reproduce the Database and Documentation and to display, sell,
license, and otherwise distribute copies of the Database or portions thereof and
the Documentation to Customers, either alone or bundled with other Pharsight
products or services; (b) to use the Database and the Documentation for purposes
of technical support for Customers; (c) to use a reasonable number of copies of
the Database and Documentation for purposes of marketing, training, and
demonstrations; (d) to use the Protocare name in connection with the
distribution and marketing of the Database and the products derived therefrom;
(e) to license Customers to use the data in the Database and to publish
summarized and non-patient-specific portions of the data, or derivatives of the
data as part of works describing their use of the data and to include the data
and derivatives of the data in regulatory submissions, (f) to authorize its
distributors to exercise any or all of the rights set forth in (a) through (e)
above; (g) to use the Database and Documentation in connection with consulting
services provided to Customers and to distribute to such Customers models and
other analyses based on the Database; and (h) to modify the Database and the
Documentation and to create derivative works of the Database and Documentation,
including incorporating the Database or


                                       1
<PAGE>

Documentation or modifications of either into an internet-based medical query
and response system, and to license the use of such system to Customers.

1.2 COPYRIGHT/TRADEMARK NOTICES. All copies of the Database distributed by
Pharsight will include appropriate copyright and trademark notices as supplied
by Protocare. Pharsight will identify the Database as a product of Protocare on
printed promotional materials and web pages that reference the Database and on
any packaging it develops.

1.3 CUSTOMER RESTRICTIONS. Customers will be licensed to use the data in the
Database and related products, including Database Derivatives, for in-house drug
development but will have no right to further distribute the Database or
Database Derivatives. The Customer license agreement for products containing the
Database or Database Derivatives will authorize use substantially as follows:
user is granted a license for the use of this product for drug discovery and
clinical development purposes. In the event that Pharsight becomes aware that
the Database or Database Derivative licensed by Pharsight to a Customer is being
used for post-approval marketing purposes, and such use is not terminated upon
notice to the Customer, Pharsight will promptly notify Protocare and the parties
will discuss the appropriate actions to take to enforce the use restrictions. If
the parties are in disagreement over the actions to take and Pharsight's actions
are not effectual in terminating the unauthorized use, Pharsight will pay to
Protocare a marketing license fee of [...***...] and Protocare will authorize
use of the Database and Database Derivatives by the Customer for post-approval
marketing purposes.

1.4 OWNERSHIP. Protocare will retain ownership of the Database and the
underlying data. Pharsight and its suppliers will own all right, title, and
interest in and to any Database Derivatives, subject to Protocare's ownership of
the underlying data and Database. Pharsight will own all right, title, and
interest in and to any query or interface or other software developed by or for
Pharsight and integrated or bundled with the Database or a Database Derivative.
Pharsight may register its own copyright in any derivative works, provided the
Database is identified in such registration as an underlying work of Protocare.
Pharsight's ownership of any Database Derivative notwithstanding, it may not
license or otherwise distribute such Database Derivative except in accordance
with the provisions of this Agreement, including the use restriction set forth
in Section 1.3.

2. DELIVERY AND ACCEPTANCE

2.1 DELIVERY OF INITIAL DATABASE. Protocare will build the Database in
accordance with the specifications in Exhibit B and test it against the
Acceptance Criteria in Exhibit C. Protocare will deliver the Database (except
for the practice review system (PRS) elements) to Pharsight electronically
within six weeks of the Effective Date; the addition of the PRS data elements
will be completed within ten weeks after the Effective Date.

2.2 ACCEPTANCE. Pharsight will have thirty (30) working days from receipt of the
Database (including the PRS elements) to test for adherence to the Acceptance
Criteria and will notify Protocare promptly if the Database fails to conform to
such criteria. Protocare will have twenty (20) working days to correct such
nonconformity, and upon redelivery Pharsight will again test the Database
against the Acceptance Criteria. This process will be repeated (except that each
subsequent test period and repair period will be limited to fifteen (15) working
days) until Pharsight either provides Protocare with written

----------------
* Confidential treatment requested.


                                       2
<PAGE>

notice of acceptance of the Database or is deemed to have accepted the Database
under the provisions of this section, provided, however, that if the Database
fails to meet the Acceptance Criteria on the third delivery, Pharsight shall
have the right to terminate this Agreement and receive a full refund of the
initial license fee. Pharsight shall be deemed to have accepted the Database if
it fails to notify Protocare of any nonconformity therein within thirty (30)
working days of delivery (or within fifteen (15) working days of redelivery in
the case of nonconformities in the original delivery).

3. PRODUCT DEVELOPMENT AND DISTRIBUTION

3.1 PRODUCT DESCRIPTION. Pharsight will distribute the Database to Customers as
part of its PIR product line. Pharsight will make PIR products available to
Customers in three forms: (a) distribution of the full Database (Direct Product
or PIR-DP); (b) use of the Database as a resource by Pharsight's professional
consultants in the course of providing consulting services (Consulting Product
or PIR-CP); and (c) use of the Database in an automated, internet-based medical
query-response service product (Internet-Product or PIR-IP).

3.2 PRODUCT DEVELOPMENT. For the PIR-DP, Pharsight will distribute the Database
either as received from Protocare or with minor changes to improve its
usability. For the PIR-CP, Pharsight employees and consultants will utilize
information from the Database in developing models that will be delivered to
customers. For the PIR-IP, Pharsight will utilize the Database as a resource
that is accessed with Pharsight proprietary query software and a customized user
interface for answering customer queries. The proprietary search software and
user interface are currently under development; Pharsight has targeted the
PIR-IP product for release in late 1999.

3.3 PRICING AND PROMOTION. Subject to the other restrictions contained in this
Agreement, Pharsight is free to price, promote, and distribute the Database in
any manner it deems appropriate. Pharsight will be responsible for all decisions
and costs involved in the marketing and distribution of the PIR, including
pricing, Customer license terms, promotional materials, packaging, distribution
channels, and customer evaluation and training. Pharsight may include material
describing the Database on its web site, in promotional materials, and during
training and professional presentations. Subject to complying with Section 1.2,
Pharsight may repackage, at its own expense, the Database products prior to
shipment to Customers and may include in such packaging the Pharsight logo,
references to Pharsight's website and other products, and the words to the
effect that the product is distributed by Pharsight.

3.4 MARKETING RESTRICTION. Pharsight will not market the PIR product containing
the Database to post-approval marketing groups. Protocare reserves all rights
not granted to Pharsight hereunder, provided, however, that Protocare agrees
that it will not market the Database to clinical development groups. In
addition, Protocare agrees that it will not market any web-based drug
development and clinical trial query and response system that is competitive
with Pharsight's internet query PIR-IP product within the disease types for
which Protocare has provided a Database to Pharsight.

3.5 COSTS. Protocare will be fully responsible for all development costs of the
Database and any updates, including any royalties or payments due to
third-parties. Pharsight will be fully responsible for any and all expenses
involved in the development of the proprietary search software and user
interface for the PIR-IP product, any other software or other tools it develops
to enhance usability of the Database, and distribution of the Database to its
customers, including manufacturing, marketing, and shipping expenses.


                                       3
<PAGE>

4. UPDATES; CUSTOMER SUPPORT

4.1 MID-YEAR UPDATES. Protocare will provide Pharsight with an update for the
Database at the half-year point of each year of this Agreement to extend the
histories of earlier selected patients by an additional six (6) months.

4.2 RENEWAL UPDATES. Protocare will provide Pharsight with totally refreshed
update (i.e., new statistical database extraction) for the Database at each
annual renewal. The refreshed Database will be subject to QA testing in
accordance with the criteria established by the parties. All copies of the prior
year database and its update held by Pharsight must be returned to Protocare
upon acceptance of the renewal update.

4.3 CUSTOMER SUPPORT. Pharsight will provide all customer support for the PIR
product. Protocare will make a person familiar with the Database available to
resolve problems Pharsight may encounter from time to time with the data
quality. For each [...***... ] in royalties paid by Pharsight to Protocare
(including the initial license fee), Protocare will provide an aggregate of two
days of problem resolution assistance without charge; further assistance will be
provided as necessary at [...***...] per day, prorated on an hourly basis for
usage of less than a full day.

5  PAYMENTS

5.1 INITIAL LICENSE FEE. Pharsight will pay Protocare a license fee of
[...***...] upon execution of this Agreement or upon the agreement of the
parties on Database fields and Acceptance Criteria, whichever is later; this
amount will be credited against actual royalties due with respect to product
sales during the initial term of this Agreement. Upon each renewal of this
Agreement, Pharsight will pay Protocare a license renewal fee of [...***...],
which will be credited against actual royalties due with respect to product
sales during the one-year renewal term. In no event may Pharsight license
products containing the Database or Database Derivatives to its Customers prior
to payment of the [...***...] license fee.

5.2 PER-COPY ROYALTY. Pharsight will pay Protocare a royalty of (i) [...***...]
for each annual license sold to a Customer for the PIR-DP containing the
Database; (ii) [...***...] for each annual license sold to a Customer for the
PIR-IP utilizing the Database or a Database Derivative; and (iii) [...***...]
for each Customer Project for which Pharsight's staff accesses the Database in
connection with providing consulting services to the Customer. For purposes of
calculating the royalty due hereunder for the PIR-DP, each copy of the media
containing the Database will constitute a separate license. For purposes of
calculating the royalty due hereunder for the PIR-IP, the clinical development
team for each therapeutic area (e.g. diabetes, cardio-vascular, etc.) shall
constitute a separate license. No royalty will be due for copies of the PIR
product used for evaluation or training.

5.3 PAYMENTS. Royalty payments will be made on a quarterly basis with payment
due thirty (30) days after the end of each calendar quarter for all revenue
received during such quarter. Refunds to Customers for products returned by
customers will be credited in the quarter in which they are returned.

----------------
* Confidential treatment requested.


                                       4
<PAGE>

Each payment will be accompanied by a report setting forth the number of each
type of product sold during the quarter.

5.4 AUDIT. Pharsight will, upon written request, during normal business hours,
but not more frequently than once each calendar year, provide access for
purposes of audit to pertinent records relating to royalties payable in
connection with the Database to an independent accounting firm chosen and
compensated (other than on a contingent fee basis) by Protocare and reasonably
acceptable to Pharsight. Such accounting firm will be authorized to report to
Protocare only the amount of royalties due and payable for the period examined.
If the amount under-reported by Pharsight is equal to or greater than ten
percent (10%) of the total payment due to Protocare for the payment period so
audited, then the cost of the audit shall be borne by Pharsight.

5.5 CONFIDENTIALITY. Protocare will not disclose to any third party any sales or
customer information received from Pharsight in connection with royalty payments
and will use such information solely for the purpose of carrying out its
obligations under this Agreement. Pharsight shall restrict access to information
contained in the Database to the person(s) assigned to analyze it or who
otherwise have a need to know it for legitimate health research purposes. Each
Customer license agreement shall require the Customer to restrict access to
information contained in the Database to person(s) assigned to analyze it or who
otherwise have a need to know it for legitimate health research purposes. Each
person given such access must first be advised that information contained in the
Database is confidential and may be used only as specifically permitted by this
Agreement or the applicable Customer license agreement and may not otherwise be
discussed or disclosed. The information contained in the Database is being
licensed to Pharsight and may be licensed to Pharsight's Customers solely for
drug discovery and development purposes, which shall include the right to
publish summarized and non-patient-specific portions of the information, or
derivatives of the information, as part of works describing their use of the
information and to include the data and derivatives of the data in regulatory
submissions, but shall not include any use that would reveal any information
from individual patient records unless so required by the FDA. Pharsight will
not and each Customer's license agreement will provide that the Customer will
not make any attempt to ascertain the names of patients or providers who are the
sources of the information contained in the Database or of any other information
that is "confidentialized" by substituting codes for identifying information
before Protocare provides Database to Pharsight. If Protocare reveals to
Pharsight the source of the data in the Database, Pharsight shall not discuss
with such source the existence of this Agreement or the business conducted
pursuant to this Agreement. Pharsight shall not name or provide information
enabling any person to determine the source of the data in any presentation,
marketing material or report unless Protocare gives its prior written consent.

6.  WARRANTIES; INDEMNIFICATION; LIMITATION OF LIABILITY

6.1 WARRANTY. Protocare warrants to Pharsight (a) that the Database does not
infringe the patent, copyright, or trade secret rights of any third party; (b)
that Protocare has all rights and authority necessary for the grant of rights
and licenses effected by this Agreement; (c) that the Database as supplied to
Pharsight was developed in accordance with the quality assurance procedures
described in Exhibit D and Exhibit E for generating and validating the data; (d)
that all appropriate and required consents to use and redistribute the data in
the Database have been obtained; and (e) that use and distribution of the
Database as authorized herein will not violate federal or state patient-privacy
laws or regulations. The warranty in clause (e) shall apply to the initial
Database only on the basis of the federal or state patient-privacy laws or
regulations in effect at the time of delivery of the initial Database. and to


                                       5
<PAGE>

each revision of the Database only on the basis of the federal or state
patient-privacy laws or regulations in effect at the time of delivery of such
revision.

6.2 INDEMNIFICATION. Protocare will defend, indemnify, and hold Pharsight
harmless from and against any action or other proceeding brought against
Pharsight to the extent that it is based on (i) a claim that any part of the
Database or Documentation infringes any copyright or patent or incorporates any
misappropriated trade secrets of any third party or (ii) a claim that use or
distribution of the Database as authorized herein violates federal or state
patient-privacy laws or regulations or the privacy rights of any patient
included in the Database as such laws were in effect at the time of delivery of
the version of the Database that is the subject of such claim (either claim, an
"Action"). Protocare will pay any and all costs, damages, and expenses
(including but not limited to reasonable attorneys' fees) incurred by Pharsight
in any such Action and will refund to Pharsight any royalties paid on any copies
of the Database for which Pharsight is required to give a refund to a Customer
because such Customer's rights to continue to use the Database have been
terminated or restricted. Protocare will have no obligation under this Section
6.2 as to any Action unless (i) Protocare is promptly notified of the Action;
(ii) Protocare has sole control of the defense and settlement of the Action; and
(iii) Pharsight provides Protocare, at Protocare' expense, with reasonable
assistance in defense and settlement of the Action. Protocare will have no
obligation under this Section 6.2 for any Action if the claim arises from the
combination, operation, or use of the Database with non-Protocare programs,
data, or documentation if such claim would have been avoided by the use of the
Database without combination with such programs, data, or documentation.

6.3 LIMITATION ON LIABILITY. EXCEPT WITH RESPECT TO THE INDEMNIFICATION
OBLIGATIONS UNDER SECTION 6.2, NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR
ANY INDIRECT, CONSEQUENTIAL, SPECIAL OR INCIDENTAL DAMAGES (INCLUDING DAMAGES
FOR LOSS OF BUSINESS PROFITS, BUSINESS INTERRUPTION, LOSS OF BUSINESS
INFORMATION, AND THE LIKE) ARISING OUT OF THIS AGREEMENT EVEN IF SUCH PARTY HAS
BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. EXCEPT WITH RESPECT TO THE
INDEMNIFICATION OBLIGATIONS UNDER SECTION 6.2, NEITHER PARTY'S LIABILITY UNDER
THIS AGREEMENT SHALL EXCEED THE AMOUNTS PAID OR PAYABLE TO PROTOCARE UNDER THIS
AGREEMENT. BOTH PARTIES ACKNOWLEDGE THAT THE FOREGOING LIMITATION REFLECTS A
BARGAINED-FOR ALLOCATION OF RISK AND THAT THE ROYALTIES SET FORTH HEREIN REFLECT
SUCH RISK.

7.  TERM AND TERMINATION

7.1 TERM OF AGREEMENT. The initial term of this Agreement will be the period
beginning on the Effective Date of this Agreement and ending on the first
anniversary of the date on which Pharsight accepts (in accordance with Section
2.2) the initial Database (including the PRS elements). This Agreement may be
renewed for two successive additional one-year periods at Pharsight's option and
beyond that may be renewed by mutual agreement of the parties.

7.2 TERMINATION FOR NON-DELIVERY. If Protocare fails to deliver the initial
Database in a form meeting the Acceptance Criteria within six (6) months of the
Effective Date, then Pharsight shall have the option to terminate this
Agreement, return any copies of the Database in its possession, and receive from
Protocare a refund of the initial license fee.


                                       6
<PAGE>

7.3 TERMINATION FOR BREACH. Each party has the right to terminate this Agreement
if the other party has materially breached any obligation herein and such breach
remains uncured for a period of thirty (30) days after written notice thereof is
sent to the other party.

7.4 EFFECT OF TERMINATION. Upon termination or expiration of this Agreement, all
rights and licenses granted to Pharsight hereunder shall terminate (except as
provided in this Section 7.4). Pharsight shall destroy all remaining copies of
the Database in its possession except for the number necessary in its judgment
to carry out its support obligations to Customers. Termination will have no
effect on the rights of any Customer to continue to use any Database in
accordance with its original license terms or on the rights of Pharsight to
provide technical support to such Customers. Notwithstanding any such
termination, Protocare shall remain entitled to fees owed pursuant to this
Agreement resulting from use or license of the Database prior to termination of
this Agreement.

8. MEDIATION AND ARBITRATION.

8.1 MEDIATION. Any dispute arising under this Agreement will be resolved through
a mediation and arbitration approach. The parties agree to select a mutually
agreeable, neutral third party to help them mediate any dispute that arises
under the terms of this Agreement. Costs and fees associated with the mediation
will be shared equally by the parties.

8.2 ARBITRATION. If the mediation is unsuccessful, the parties agree that the
dispute will be decided by binding arbitration under the rules of the American
Arbitration Association. The decision of the arbitrators will be final and
binding on the parties and may be entered and enforced in any court of competent
jurisdiction by either party. The prevailing party in the arbitration
proceedings will be awarded reasonable attorney fees, expert witness costs and
expenses, and all other reasonable costs and expenses incurred in connection
with the proceedings, unless the arbitrators for good cause determine otherwise.

9. GENERAL

9.1 NOTICES. Any notice required or permitted hereunder must be in writing, and
will be effective on the date of delivery when delivered personally, the next
business day after dispatch when sent by Federal Express or other recognized
overnight courier service, or the fifth business day after dispatch when sent by
certified mail, postage prepaid, return receipt requested. Notices should be
addressed to the other party at the address shown below or at such other address
as a party may designate by ten days' advance written notice to the other party:

      Pharsight Corporation                      Protocare Sciences, Inc.
      800 West El Camino Real, Suite 200         2400 Broadway
      Mountain View, CA  94040                   Santa Monica, CA 90404
      Attention:  Chief Financial Officer        Attn: Chief Executive Officer
      Phone: (650) 314-3800                      Phone:
      Fax: (650) 314-3810                        Fax:

9.2 ENTIRE AGREEMENT; MODIFICATIONS. This Agreement, including all exhibits,
constitutes the entire agreement of the parties with respect to the subject
matter hereof and supersedes all prior


                                       7
<PAGE>

representations, proposals, discussions, and communications, whether oral or in
writing. This Agreement may be modified or amended only by a writing executed by
a duly authorized representative of each party.

9.3 FORCE MAJEURE. Neither party will be liable to the other for any failure or
delay caused by events beyond such party's control, including, without
limitation, sabotage, riots, insurrections, fires, flood, storm, explosions,
war, or earthquakes. However, if such events shall continue for thirty (30) days
or more, the other party shall have the option of terminating this Agreement by
giving written notice of termination.

9.4 CHANGE IN LAW; CHANGE IN CIRCUMSTANCES. No party shall make or receive any
payment or take any action under this Agreement if any judicial decision,
legislative action, or regulatory or other administrative interpretation,
whether federal or state, would render illegal the conduct of either party under
this Agreement. If performance by either party of any term of this Agreement
should be deemed illegal by any party or third party who is essential to
performance of this Agreement for any such reason, either party shall have the
right to require that the other party renegotiate the terms of this Agreement.
If Protocare's data relationships shall be altered or interrupted, Protocare
shall notify Pharsight and the parties shall attempt to renegotiate the terms of
this Agreement. If the parties fail to reach an agreement satisfactory to both
parties within fifteen (15) days after the receipt of any request for
renegotiation, either party may terminate this Agreement upon fifteen (15) days
prior written notice to the other party, or sooner if required by law. In the
event of such termination, Protocare will refund to Pharsight a pro-rated amount
of the [...*** ...] initial licensing fee or renewal license fee paid for the
year in which termination occurs.

9.5 ASSIGNMENT. This Agreement will be binding upon and inure to the benefit of
the parties hereto, their successors and permitted assigns. Either party may
assign this Agreement in its entirety to a successor corporation upon notice to
the other party in the event of a merger or an acquisition of all or
substantially all of the assets of the assigning party.

9.6 GOVERNING LAW. All questions concerning the validity, operation,
interpretation, and construction of this Agreement will be governed by and
determined in accordance with the laws of the State of California, without
regard to its conflict of laws provisions. Application of the United Nations
Convention on Contracts for the International Sale of Goods is specifically
excluded.

9.7 SEVERABILITY. If a court of competent jurisdiction determines that any
provision of this Agreement is invalid, illegal, or otherwise unenforceable,
such provision shall be replaced with a valid, enforceable provision as nearly
as possible in accordance with the stated intention of the parties, while the
remainder of this Agreement shall remain in full force and effect. To the extent
any provision cannot be enforced in accordance with the stated intentions of the
parties, such provision shall be deemed not to be a part of this Agreement.

9.8 COUNTERPARTS. This Agreement may be executed in any number of counterparts,
all of which together will constitute one and the same instrument.

----------------
* Confidential treatment requested.


                                       8
<PAGE>

IN WITNESS THEREOF, THE PARTIES HAVE CAUSED THIS AGREEMENT TO BE EXECUTED BY
THEIR RESPECTIVE DULY AUTHORIZED REPRESENTATIVES AS SET FORTH BELOW:

PHARSIGHT CORPORATION                          PROTOCARE SCIENCES, INC.

By:   /s/  Robin A. Kehoe                      By: /s/  Robert Dubois
   ------------------------------                 ------------------------------
Robin A. Kehoe                                 Robert  Dubois
Chief Financial Officer                        Chief Executive Officer


                                       9
<PAGE>

                                    EXHIBIT A

                                   DEFINITIONS

DATABASE means the diabetes database as described in Exhibit B and all updates
to the initial database when and as delivered to Pharsight.

DATABASE DERIVATIVE means any derivative works, modifications, or new
compilations of the Database prepared by or on behalf of Pharsight.

DOCUMENTATION means any and all materials provided to Pharsight by Protocare
describing the features, structure, functions, fields, contents, collection
methods, etc. of the Database.

CUSTOMER means a customer of Pharsight or of its distributors to whom Pharsight
has licensed the use of the Database or Database Derivatives or to whom
Pharsight has provided services utilizing the Database or Database Derivatives.

CUSTOMER PROJECT means a set of consulting services provided to a Customer by
Pharsight pursuant to a single statement of work with respect to a single drug
or related set of drugs. A single Customer Project may include follow-on work
based on the results of the initial work so long as the possibility of such
follow-on work is contemplated in the original statement of work.

ACCEPTANCE CRITERIA means the quality requirements for the Database set forth in
Exhibit C or otherwise agreed upon in writing by the parties.


                                       10
<PAGE>

                                    EXHIBIT B

                    PHARSIGHT DIABETES DATABASE SPECIFICATION

Using claims from January 1, 1997 through December 31, 1997, all patients who
meet the following criteria for diabetes will be identified:

[...***...]


The data files will be delivered to Pharsight on CDs as 1) Version 5 SAS
Transport Format and 2) Fixed format ASCII files with an accompanying Oracle 7
SQL*Loader control file describing their layout, datatypes, etc.

[...***...]


----------------
* Confidential treatment requested.


                                       11
<PAGE>

                                    EXHIBIT C

                               ACCEPTANCE CRITERIA

[to be agreed upon]


                                       12
<PAGE>

                                    EXHIBIT D

                      DATABASE QUALITY ASSURANCE PROCEDURES

When building a database for a client, there are specific steps taken by the
database analyst to assure quality:

POPULATION SELECTION AND DATA ACQUISITION

1.   [...***...]

DATA SCRUBBING

2.   Once all claims are assembled, our analyst `scrubs' the data to assure
     completeness of each field. The following document outlines check list for
     the data quality edits:

DATA SCRUBBING EDIT CHECKS

[...***...]

DATABASE ELEMENT INCLUSION CHECK LIST:

[...***...]


----------------
* Confidential treatment requested.


                                       13
<PAGE>

                                    EXHIBIT E

         PROTOCARE SCIENCES DATA WAREHOUSE QUALITY ASSURANCE PROCEDURES

Protocare Sciences maintains an in-house proprietary database comprised of
claims and eligibility records from patient populations covered under various
benefit plans. Protocare receives monthly paid claims files from the plans and
"scrubs" the data for entry into the warehouse. The warehouse is updated on a
quarterly basis. The data cleansing process begins prior to extracts being sent
to Protocare. The typical process is as follows:

        1.  Protocare works with the data source to assign a quality level to
            the data. Issues that are of highest importance in determining data
            quality are: the percentage of complete encounter claims, usually
            for capitated services, that are included in the claims source; the
            predominant coding schemes used for diagnoses and procedures,
            preferably ICD-9-CM, CPT4, and HCPCS; and, the ability to uniquely
            identify members/patients across all types of data within the
            source.
        2.  Protocare works with the data source to address volume and
            processing issues, "claims experts" who can address current and
            historic issues with the data source, and business analysts who
            currently use the data and are aware of its anomalies.
        3.  Prior to receiving all claims from the data source, Protocare asks
            the source to send a sample extract of all data formats for further
            analysis. Protocare typically evaluates eligibility, provider, and
            claims data formats. The values stored within the sample data are
            compared to data dictionary and database questionnaire information.
        4.  When this process is complete, Protocare asks the source to send a
            historic load. Before loading the data into the, the data is
            "scrubbed".
        5.  For claims, the scrubbing process includes subsetting the raw,
            source data to include only those data elements of interest to
            Protocare; including only final, paid claims; and, verifying that
            dollar fields at the line level for each claim sum to the claim
            level values. Data are not deleted if they contain invalid
            diagnosis, procedure, or NDC codes; however, reference files are
            available to compare these codes to valid values. On a study by
            study basis, inappropriate or incorrect diagnostic, procedural, and
            drug codes are removed.
        6.  For eligibility, the scrubbing process includes collapsing multiple
            eligibility records for a patient into one continuous record and
            supplementing the demographic fields (such as residence state) with
            information from claims data when the information is not available
            in the eligibility file.

The Protocare data warehouse is stored in a relational database. These data are
arrayed in chronological order to provide a very detailed longitudinal profile
of all medical and pharmacy services used by a patient. Services typically
include the following types of information: demographics, inpatient and
outpatient diagnoses by ICD-9-CM codes, inpatient and outpatient procedures,
billed and reimbursed charges, outpatient drugs dispensed, and dates of service
for drug and medical information.

As stated above, the data scrubbing process does not exclude claims that may
have "homegrown" or "invalid" diagnosis, procedure, or outpatient pharmacy drug
codes. Many times, invalid codes contribute to an analysis. For example, the
diagnosis code "250" (diabetes) is invalid because fourth and/or fifth digits
are required in reporting diabetes diagnoses; however, a claim with this
diagnosis indicates that a patient was treated for diabetes. It just does not
specify what type of diabetes. In conducting a cost and utilization analysis,
excluding this claim would result in under representation of the condition of
diabetes. These claims can easily be excluded from an analysis if it is
appropriate.


                                       14
<PAGE>

Protocare employs a team of experts who are skilled in data extraction, data
hygiene and cleansing, and data translation and manipulation. Within the data
warehouse:

        -   Data extraction is accomplished in one of three ways: (1) ad hoc
            isql queries to unload tables and/or fields of interest, (2) Oracle
            applications to create subsets of the relational database, or (3) ad
            hoc isql queries to ASCII files which are then loaded into
            SAS-Registered Trademark- for further analysis.
        -   Data cleansing is performed prior to loading the data into the
            Protocare warehouse. Additional "data hygiene" activities are
            executed on an ad hoc, project by project basis. The most common of
            these activities are to compare diagnosis, procedure, and drug codes
            to reference sources to determine the validity of each code used in
            a study.
        -   The data can be translated and manipulated in many ways through the
            use of analysis tools such as SAS-Registered Trademark-. Common
            manipulations include building inpatient hospitalization shells from
            all of the facility and professional claims that are associated with
            each hospitalization. From these shells, inpatient length of stay
            and total cost of services can be captured. Additional data
            manipulation may include data summarizations across key dimensions
            such as the types of services provided within different provider
            specialties or the number and type of drug classes used in treating
            a specific condition. Finally, we can apply PRS to the claims data
            to create a more enhanced database.


                                       15